- Home
- MREO vs ALT Comparison
MREO vs ALT Comparison
Compare MREO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | ALT |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 576.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MREO | ALT |
|---|---|---|
| Price | $2.00 | $3.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.20 | ★ $16.33 |
| AVG Volume (30 Days) | 2.4M | ★ 4.5M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $131.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.47 | $2.90 |
| 52 Week High | $3.88 | $8.75 |
Technical Indicators
Market Signals| Indicator | MREO | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 31.76 |
| Support Level | $1.89 | $4.92 |
| Resistance Level | $2.37 | $5.37 |
| Average True Range (ATR) | 0.17 | 0.42 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 40.48 | 1.36 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.